BNP Paribas Financial Markets
RAPT

BNP Paribas Financial Markets’s RAPT Therapeutics RAPT Stock Holding History

BNP Paribas Financial Markets’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-498
Closed -$16.9K – 6065
2025
Q4 		$16.9K Buy
498
+419
+530% +$13K ﹤0.01% 5062
2025
Q3 		$2.04K Sell
79
-56
-41% -$733 ﹤0.01% 5169
2025
Q2 		$1.08K Sell
135
-114
-46% -$870 ﹤0.01% 5137
2025
Q1 		$2.42K Sell
249
-274
-52% -$2.69K ﹤0.01% 4961
2024
Q4 		$6.61K Buy
+523
New +$6.64K ﹤0.01% 4897

BNP Paribas Financial Markets's RAPT Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 498 shares — an estimated $16.9K sold.

BNP Paribas Financial Markets first reported a position in RAPT in Q4 2024 and held it in 5 quarters. The position peaked at $16.9K in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • BNP Paribas Financial Markets reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 498 RAPT Therapeutics shares in Q1 2026, an estimated $16.9K.
  • BNP Paribas Financial Markets first reported a position in RAPT Therapeutics in Q4 2024 and held it in 5 quarters.
  • BNP Paribas Financial Markets's RAPT Therapeutics position peaked at $16.9K in Q4 2025.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.